SMAD2 and neoplasm: Specifically, assessing the levels of biomarkers related with TGFβ1 signaling and cellular quiescence —such as endoglin, P-SMAD2 and P21— in tumor biopsies, alongside measuring TGFβ1 levels in patient serum, could provide valuable insights to anticipate the appearance of resistant responses to MAL-PDT.